Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide + vindesine + valproic acid
- Development stage
- Phase 2
- Lead developer
- European Lung Cancer Working Party
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen consisting of four drugs: - **Doxorubicin** (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - **Cyclophosphamide** (an alkylating agent that crosslinks DNA) - **Vindesine** (a vinca alkaloid that inhibits microtubule assembly) - **Valproic acid** (a histone deacetylase inhibitor with epigenetic modulatory effects) The combination has been studied as a salvage therapy for patients with refractory or relapsing small cell lung cancer (SCLC) after failure of platinum-based regimens. Valproic acid is included to enhance the cytotoxicity of the VAC regimen through epigenetic modulation and increased apoptosis in tumor cells. The mechanism involves both intrinsic and extrinsic apoptotic pathways via caspase activation. This regimen has shown some activity in phase II clinical trials but did not significantly improve progression-free survival compared to historical controls[1][2][3].
- Other names
- doxorubicincyclophosphamidevindesinevalproic acidVAC plus valproic acid
02
Targets
DNAdsDNA (Double-stranded DNA)Class IIa histone deacetylaseHDAC (HDAC family)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide + vindesine + valproic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide + vindesine + valproic acid.